Vivos Therapeutics, Inc. (VVOS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Vivos Therapeutics, Inc. (VVOS)
Company Performance

Current Price

as of Oct 16, 2024

$2.53

P/E Ratio

N/A

Market Cap

$12.06M

Description

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Metrics

Overview

  • HQLittleton, CO
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerVVOS
  • Price$2.53+2.43%

Trading Information

  • Market Cap$12.06M
  • Float89.82%
  • Average Daily Volume (1m)418,541
  • Average Daily Volume (3m)1,334,214
  • EPS-$6.30

Company

  • Revenue$14.02M
  • Rev Growth (1yr)19.41%
  • Net Income-$1.93M
  • Gross Margin61.82%
  • EBITDA Margin-44.18%
  • EBITDA-$1.79M
  • EV$2.03M
  • EV/Revenue0.14
  • P/EN/A
  • P/S0.58
  • P/B1.36
Documents
SEC Filings
8-K (2024-09-20)
8-K (2024-09-18)
8-K (2024-09-17)
8-K (2024-09-12)
8-K (2024-08-15)
8-K (2024-07-10)
8-K (2024-06-25)
8-K (2024-06-14)
8-K (2024-05-17)
8-K (2024-05-15)
8-K (2024-05-06)
8-K (2024-03-29)
8-K (2024-02-15)
8-K (2023-11-30)
8-K (2023-11-02)
8-K (2023-10-27)
8-K (2023-09-25)
8-K (2023-09-21)
8-K (2023-08-21)
8-K (2023-08-16)
8-K (2023-06-08)
8-K (2023-05-26)
8-K (2023-05-09)
8-K (2023-03-30)
8-K (2023-03-27)
8-K (2023-03-02)
8-K (2023-01-09)
10-Q (2024-08-14)
10-Q (2024-05-14)
10-Q (2023-11-14)
10-Q (2023-08-16)
10-Q (2023-06-08)
10-K (2024-03-28)
10-K (2023-03-30)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-17)
Earnings Report (2023-06-09)
Factset
Factset Business Description
Factset Street Account
Vivos Therapeutics signs nationwide distribution agreement with Lincare ($0.28, 0.00) (2023-10-24T11:35:18Z)
Vivos Therapeutics reports Q3 EPS ($1.75) vs year-ago ($6.40) ($3.73, 0.00) (2023-11-14T21:20:07Z)
Vivos Therapeutics receives FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea ($4.39, 0.00) (2023-11-29T12:32:52Z)
Vivos Therapeutics enters exclusive distribution agreement with NOUM DMCC ($0.30, 0.00) (2023-10-05T11:32:59Z)
Vivos Therapeutics Announces 1-for-25 Reverse Stock Split; effective 27-Oct-23 ($0.28, 0.00) (2023-10-26T11:33:56Z)